J Haem Pract 2016; 3(1):1-3. doi: 10.17225/jhp00071

Authors: Cedric Hermans

Cedric Hermans
Head Division of Haematology
Haemostasis and Thrombosis Unit, Haemophilia Clinic, St-Luc University Hospital, Avenue Hippocrate 10, 1200 Brussels, Belgium. Email:


The long-awaited results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were recently presented during a plenary session at the American Society of Hematology (ASH) conference in December 2015.


This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited




  1. Peyvandi F, Mannucci PM, Garagiola I, et al. Source of Factor VIII Replacement (plasmatic or recombinant) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study. Presented at American Society of Hematology. December, 2015.
  2. Gouw SC, van den Berg HM, Fischer K, et al; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121(20): 4046-55. doi: 10.1182/blood-2012-09-457036.
  3. Andrea Messori A. The SIPPET trial and the economic consequences of developing high-titre inhibitors in hemophilia A. BMJ 2015; 350:h870

The Journal of Haemophilia Practice is published by Haemnet.

Haemnet is a registered charity that brings together and gives a voice to haemophilia nurses, physiotherapists and allied health care professionals, providing forums for collaborative research, educational activities and support.